(Q37816414)

23 August 2017

1 reference

title

Applications of 'decisionable' biomarkers in cardiovascular drug development (English)

1 reference

23 August 2017

0 references

Rajesh Krishna

1

1 reference

23 August 2017

John A Wagner

series ordinal

2

1 reference

23 August 2017

publication date

1 December 2010

1 reference

23 August 2017

published in

Biomarkers in Medicine

1 reference

23 August 2017

volume

4

1 reference

23 August 2017

issue

6

1 reference

23 August 2017

page(s)

815-827

1 reference

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Strategic approach to fit-for-purpose biomarkers in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Proof of concept: a PhRMA position paper with recommendations for best practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Overview of biomarkers and surrogate endpoints in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

A cost-effectiveness approach to the qualification and acceptance of biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

The clinical utility index as a practical multiattribute approach to drug development decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

The use of clinical utility assessments in early clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Model-based drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Drug treatment of lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

A high-precision fluorogenic cholesteryl ester transfer protein assay compatible with animal serum and 3456-well assay technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Biochemical characterization of cholesteryl ester transfer protein inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Effect of torcetrapib on the progression of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Direct renin inhibition and the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Pharmacokinetic/pharmacodynamic modeling of renin biomarkers in subjects treated with the renin inhibitor aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.10.107

21 January 2018

Identifiers

DOI

10.2217/BMM.10.107

1 reference

23 August 2017

1 reference